Drug Database
IN

interferon alpha 2b

✓ Approved

Helvetic Biopharma · IFNAR2 · Recombinant Proteins

What is interferon alpha 2b?

interferon alpha 2b is a recombinant proteins developed by Helvetic Biopharma. It is approved for therapeutic indications via injectable (others).

Drug Profile

CompanyHelvetic Biopharma
Drug ClassRecombinant Proteins
Molecular TargetIFNAR2
RouteInjectable (Others)
StatusApproved

Mechanism of Action

Molecular Targets

interferon alpha 2b acts on 1 molecular target:

IFNAR2interferon alpha and beta receptor subunit 2 (IFNARB, IFN-alpha-REC)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

interferon alpha 2b is developed for 10 unique indications across 2 therapeutic areas.

Therapeutic AreaConditionPhase
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Basal cell carcinoma✓ Approved
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Bladder cancer✓ Approved
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Hairy cell leukaemia✓ Approved
Infections and infestationsHepatitis B✓ Approved
Infections and infestationsHepatitis C✓ Approved

+5 more indications available with a free account

Sign up free to view all indications →

Related Research Articles

PubMedACG case reports journal2026-07-17

Colonic Ischemia Without Mesenteric Occlusion: A Case Implicating Interferon-β.

Siegel Alexander A, Tun Kyaw Min KM, Gamache Jennifer J, Kizer Robert R

Type I interferons are commonly used immunomodulatory agents. Interferon-α (interferon-α) has been associated with ischemic colitis, but cases linking interferon-β (IFN-β) to ischemic colitis are rare. We present a 66-year-old woman with multiple sclerosis treated with IFN-β who developed acute abdominal pain and diarrhea. Imaging demonstrated right-sided colonic inflammation with pneumatosis. Colonoscopy with tissue biopsy confirmed ischemic colitis, despite patent mesenteric vasculature on angiographic imaging. Her symptoms resolved after discontinuation of IFN-β. This case highlights IFN-β as a potential cause of nonocclusive ischemic colitis and underscores the importance of recognizing ischemic complications in patients treated with IFN-β.

PubMedbioRxiv : the preprint server for biology2026-07-17

Distinct macrophage and T cell programs shape pancreatic inflammation during metabolic stress and aging.

Sai Somesh S, Omar Ibrahim I, Barone Matthias M, Mühle Kerstin K et al.

Type 2 diabetes is linked to systemic inflammation driven by metabolic stress and aging. Although pancreatic inflammation associated with these factors is well documented, the dynamics of immune cell populations and their molecular changes remain poorly understood. We characterized immune cell alterations in the pancreas and pancreatic islets during Western diet (WD) feeding and aging using imaging mass cytometry (IMC) and single-cell RNA sequencing (scRNA-seq). Spatial and transcriptional analyses were performed to define immune cell subtype composition, activation states, and inferred cell-cell communication programs under metabolic and age-related stress conditions. Our analyses identified expansion of an F4/80 low macrophage subtype and activated effector-like CD8 + T cells throughout the pancreas during WD feeding and aging. Within pancreatic islets, single-cell RNA sequencing identified a type I interferon-responsive macrophage population with low F4/80 expression that expanded during overnutrition. Notably, the type I interferon responses elicited by these stressors diverged: aging was associated with a more canonical type I interferon response, whereas overnutrition induced a broader response that included STAT3-associated transcriptional programs. We further provide evidence for enhanced cytokine-mediated communication between macrophages and a CD8 + cytotoxic T-cell population under overnutrition and aging. These findings show that metabolic stress and aging remodel pancreatic inflammation through overlapping but distinct immune mechanisms, involving expansion of F4/80 low macrophages, activation of divergent type I interferon programs, and enhanced macrophage-CD8 + T-cell communication. Together, these findings suggest that distinct therapeutic approaches may be required to preserve islet function in type 2 diabetes driven by metabolic stress versus aging. Metabolic stress and aging remodel pancreatic inflammation through overlapping but distinct immune mechanisms.Spatial and single-cell analyses identified conserved remodeling of pancreatic macrophage populations accompanied by activation of cytotoxic T-cell responses during metabolic stress and aging.In pancreatic islets, macrophages exhibited distinct type I interferon-associated transcriptional programs, with aging showing a more canonical interferon response and metabolic stress eliciting a broader inflammatory program that included STAT3-associated transcriptional signatures.These findings provide a framework for understanding how metabolic stress and aging differentially shape pancreatic inflammation.

PubMedmedRxiv : the preprint server for health sciences2026-07-17

Standardized, repeatable ulcerative colitis histology scoring and endpoint assessment using an automated, foundation model-based tool.

Tahir Waleed W, Shamshoian John J, Tauber John J, Clinton Lani K LK et al.

In clinical trials for ulcerative colitis (UC), pathologists assess disease severity through standardized histological indices, including the Geboes Score, Robarts Histopathology Index (RHI), and Nancy Histologic Index (NHI). Despite strong associations with clinical outcomes, histologic scoring suffers from inter- and intra-reader variability, and consensus criteria for histologic remission remain uncertain. Through a consortium approach, we developed an artificial intelligence-based measurement (AIM) tool for scoring histology in UC mucosal biopsies (AIM-HI UC). This model, trained on a large dataset of UC biopsies (N=10,230), utilizes additive multiple instance learning models leveraging PLUTO, a pathology foundation model, that predict each of the Geboes subgrades, from which the Geboes grade-level score, RHI, and NHI can be calculated. Evaluation of this model on a standalone verification set including clinical trial specimens established algorithm non-inferiority and/or superiority relative to standard qualified pathologists through comparison of algorithm-consensus and pathologist-consensus agreement metrics (non-inferior if difference >-0.1, superior if difference >0, inclusive of confidence intervals). AIM-HI UC was determined to be non-inferior to pathologists (N=3) for the prediction of all seven Geboes subgrades, grade-level Geboes, RHI, NHI, histologic improvement (GS < 3.1), 2A histologic remission (GS<2A.0), and 2B histologic remission (GS<2B.0). AIM-HI UC was superior to pathologists for several Geboes subgrades (GS 0, GS 1, GS 2B, and GS 5), as well as grade-level Geboes, RHI, and positive percent agreement of 2A histologic remission. The model was shown to be greater than 99% repeatable for all histologic scoring metrics examined. Model-derived scores were shown to strongly correlate with canonical histologic features of inflammation, including the proportion of total epithelium that is inflamed (Spearman r=0.83; p<0.01), the proportion of neutrophils localized within crypt epithelium (Spearman r=0.83, p<0.01), and the amount of mucosal area classified as erosion or ulceration (Spearman r=0.80, p<0.01). Overall, these results suggest that AIM-HI UC has the potential to improve consistency of UC histology interpretation, providing a path toward standardization of UC histology scoring in clinical trials.

PubMedMonaldi archives for chest disease = Archivio Monaldi per le malattie del torace2026-07-17

Removal of Expression of Concern for 'Interferon-γ release assay'.

Publisher The T

Removal of Expression of Concern for 'Interferon-γ release assay' by Malay Sarkar and Jasmine Sarkar, Accepted Manuscript, https://doi.org/10.4081/monaldi.2025.3258 The Publisher of the Monaldi Archives for Chest Disease is publishing this removal of expression of concern to inform readers that the investigation is complete and all earlier issues have been addressed. This notice supersedes the information provided in the Expression of Concern related to this article (https://doi.org/10.4081/monaldi.2025.3712).

PubMedCellular & molecular immunology2026-07-17

Author Correction: DNA sensing and associated type 1 interferon signaling contributes to progression of radiation-induced liver injury.

Du Shisuo S, Chen Genwen G, Yuan Baoying B, Hu Yong Y et al.

PubMedResearch square2026-07-17

Biallelic mutations in SUPV3L1 cause a variable leukodystrophy due to impaired mitochondrial degradosome function.

Green Lydia L, Hamilton Noémie N, Elpidorou Marilena M, Maroofian Reza R et al.

Purpose Sensing and degradation of double stranded RNA (dsRNA) in the cell is tightly regulated to avoid activation of type I interferon signalling. The mitochondrial dsRNA degradosome complex is formed by PNPT1 and SUPV3L1. While biallelic PNPT1 mutations are an established cause of early-onset encephalopathy, the clinical and radiological impact of SUPV3L1 dysfunction is yet to be fully defined. Methods Through an international collaboration, we identified 21 patients with biallelic SUPV3L1 mutations. Available clinical and radiological data were compared. A supv3l1 knock-out zebrafish was generated to investigate the impact of supv3l1 loss in vivo . Results Fifteen different biallelic loss-of-function SUPV3L1 variants were identified in twenty-one individuals presenting with a wide clinical spectrum including neonatal haematological disturbance, infant-onset motor disorder and acute encephalopathy. Most individuals demonstrated significant neurodevelopmental involvement, manifesting as moderate to severe motor delay with intellectual impairment. Other common clinical features include microcephaly and spasticity. Three out of four patients tested showed an increased interferon signature in peripheral blood. A supv3l1 knock-out zebrafish exhibited defective mitochondria morphology and microglial function, with a significant activation of type 1 interferon signalling. Conclusion We define the genetic, clinical and radiological spectrum of SUPV3L1 -asociated disease and suggest activation of the type 1 interferon innate immune pathway by dysplastic microglia as a possible underlying cause.

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about interferon alpha 2b